<div class="headers"><div>Figure 3. Abdominal pain subscores in patients with CD. Percentage change from baseline in APS in overall ITT (A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations and percentage change from baseline in LSFS in overall ITT (D), TNF antagonist-naive (£), and TNF antagonist-exposed (F) populations after VDZ or PBO administration. ®Data points represent adjusted % change from BL mean, where adjustment is for subscore BL value and treatment. Error bars represent SE. ‘’Difference adjusted % change [VDZ - PBO] = % = adjusted mean % change from BL for VDZ - adjusted mean % change from BL for PBO. Upper limit of 95% Cl <0 indicates statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. Patients with baseline APS = 0 or LSFS = 0 were excluded from this analysis. APS, abdominal pain subscore; BL, baseline; Cl, confidence interval; ITT, intent-to-treat; LSFS, loose stool frequency subscore; NS, nonsignificance; PBO, placebo; SE, standard error; VDZ, vedolizumab.</div></div><table class='gmisc_table' style='border-collapse: collapse; margin-top: 1em; margin-bottom: 1em;' >
<tbody>
<tr style='border-top: 2px solid grey;'>
<td style='border-top: 2px solid grey; border-bottom: 2px solid grey; text-align: left;'><p style="" class="">Figure 3. Abdominal pain subscores in patients with CD. Percentage change from baseline in APS in overall ITT (A), TNF antagonist-naive (S), and TNF antagonist-exposed (C) populations and percentage change from baseline in LSFS in overall ITT (D), TNF antagonist-naive (£), and TNF antagonist-exposed (F) populations after VDZ or PBO administration. ®Data points represent adjusted % change from BL mean, where adjustment is for subscore BL value and treatment. Error bars represent SE. ‘’Difference adjusted % change [VDZ - PBO] = % = adjusted mean % change from BL for VDZ - adjusted mean % change from BL for PBO. Upper limit of 95% Cl <0 indicates statistical significance at a nominal significance level of 0.05. ‘Statistical significance and nonsignificance. Patients with baseline APS = 0 or LSFS = 0 were excluded from this analysis. APS, abdominal pain subscore; BL, baseline; Cl, confidence interval; ITT, intent-to-treat; LSFS, loose stool frequency subscore; NS, nonsignificance; PBO, placebo; SE, standard error; VDZ, vedolizumab.</p></td>
</tr>
</tbody>
</table>
